Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single rising subcutaneous dose study of BI 3006337 in healthy male volunteers
NL-OMON51833Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of YH25724 in metabolic dysfunction-associated steatohepatitis (MASH) (22 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Nov 2022; status: completed.
02
Drugs
YH25724
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON51833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51833.